Human Organoids Market by Product (Liver, Kidney, Pancreatic Models (2D, 3D)), Disease Area (Oncology, GI, Neurological Disorders), Application (Drug Toxicity, Personalized Medicine), End User (Pharma & Biotech Companies, CROs) - Global Forecast to 2029

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 STUDY OBJECTIVES
• 1.2 MARKET DEFINITION
• 1.3 STUDY SCOPE
  • 1.3.1 MARKETS COVERED & REGIONAL SCOPE
  • 1.3.2 INCLUSIONS & EXCLUSIONS
  • 1.3.3 YEARS CONSIDERED
  • 1.3.4 CURRENCY CONSIDERED
• 1.4 STAKEHOLDERS
• 1.5 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

• 2.1 RESEARCH DATA
• 2.2 RESEARCH APPROACH
  • 2.2.1 SECONDARY DATA
    • 2.2.1.1 Key data from secondary sources
  • 2.2.2 PRIMARY DATA
    • 2.2.2.1 Primary sources
    • 2.2.2.2 Key data from primary sources
    • 2.2.2.3 Key industry insights
    • 2.2.2.4 Breakdown of primary interviews
• 2.3 MARKET SIZE ESTIMATION
  • 2.3.1 BOTTOM-UP APPROACH
    • 2.3.1.1 Approach 1: Company revenue estimation approach
    • 2.3.1.2 Approach 2: Presentations of companies and primary interviews
    • 2.3.1.3 Growth forecasts
    • 2.3.1.4 CAGR projections
  • 2.3.2 TOP-DOWN APPROACH
• 2.4 MARKET BREAKDOWN AND DATA TRIANGULATION
• 2.5 MARKET SHARE
• 2.6 ASSUMPTIONS & LIMITATIONS
  • 2.6.1 STUDY ASSUMPTIONS
  • 2.6.2 GROWTH RATE ASSUMPTIONS
  • 2.6.3 LIMITATIONS
• 2.7 RISK ASSESSMENT
  • 2.7.1 RISK ASSESSMENT: HUMAN ORGANOIDS MARKET

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

• 4.1 HUMAN ORGANOIDS MARKET OVERVIEW
• 4.2 HUMAN ORGANOIDS MARKET, BY PRODUCT, 2024 VS. 2029
• 4.3 HUMAN ORGANOIDS MARKET, BY SOURCE, 2024 VS. 2029
• 4.4 HUMAN ORGANOIDS MARKET, BY TYPE, 2024 VS. 2029
• 4.5 HUMAN ORGANOIDS MARKET, BY APPLICATION, 2024 VS. 2029
• 4.6 HUMAN ORGANOIDS MARKET, BY END USER, 2024 VS. 2029
• 4.7 HUMAN ORGANOIDS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES

5 MARKET OVERVIEW

• 5.1 INTRODUCTION
• 5.2 MARKET DYNAMICS
  • 5.2.1 DRIVERS
    • 5.2.1.1 Growing focus on developing alternatives to animal testing
    • 5.2.1.2 Rising R&D funding and venture capital investments
    • 5.2.1.3 Increasing research on organoids
    • 5.2.1.4 Increasing prevalence of non-alcoholic fatty liver disease
    • 5.2.1.5 Need for early detection of drug toxicity to minimize financial losses caused by late-stage drug failure
  • 5.2.2 RESTRAINTS
    • 5.2.2.1 Issues related to incorporating organoids into existing workflows
  • 5.2.3 OPPORTUNITIES
    • 5.2.3.1 Increasing focus on drug discovery activities
    • 5.2.3.2 Rising demand for organ transplantation
    • 5.2.3.3 Growth opportunities in emerging economies
  • 5.2.4 CHALLENGES
    • 5.2.4.1 Dearth of skilled professionals
• 5.3 PRICING ANALYSIS
  • 5.3.1 AVERAGE SELLING PRICE, BY PRODUCT
  • 5.3.2 AVERAGE SELLING PRICE, BY REGION
• 5.4 PATENT ANALYSIS
  • 5.4.1 LIST OF MAJOR PATENTS
• 5.5 VALUE CHAIN ANALYSIS
• 5.6 SUPPLY CHAIN ANALYSIS
• 5.7 TRADE ANALYSIS
  • 5.7.1 IMPORT DATA (HS CODE 3002)
  • 5.7.2 EXPORT DATA (HS CODE 3002)
• 5.8 ECOSYSTEM ANALYSIS
  • 5.8.1 ROLE IN ECOSYSTEM
• 5.9 PORTER'S FIVE FORCES ANALYSIS
  • 5.9.1 THREAT OF NEW ENTRANTS
  • 5.9.2 THREAT OF SUBSTITUTES
  • 5.9.3 BARGAINING POWER OF BUYERS
  • 5.9.4 BARGAINING POWER OF SUPPLIERS
  • 5.9.5 INTENSITY OF COMPETITIVE RIVALRY
• 5.10 KEY STAKEHOLDERS AND BUYING CRITERIA
  • 5.10.1 KEY STAKEHOLDERS IN BUYING PROCESS
  • 5.10.2 KEY BUYING CRITERIA
• 5.11 REGULATORY LANDSCAPE
  • 5.11.1 KEY REGULATIONS
    • 5.11.1.1 North America
      • 5.11.1.1.1 US
      • 5.11.1.1.2 Canada
    • 5.11.1.2 Europe
    • 5.11.1.3 Asia Pacific
      • 5.11.1.3.1 China
      • 5.11.1.3.2 Japan
      • 5.11.1.3.3 India
    • 5.11.1.4 Latin America
      • 5.11.1.4.1 Brazil
      • 5.11.1.4.2 Mexico
    • 5.11.1.5 Middle East & Africa
  • 5.11.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • 5.11.2.1 North America
    • 5.11.2.2 Europe
    • 5.11.2.3 Asia Pacific
    • 5.11.2.4 Latin America
    • 5.11.2.5 Rest of the world
• 5.12 TECHNOLOGY ANALYSIS
  • 5.12.1 KEY TECHNOLOGIES
    • 5.12.1.1 Stem Cell Technology
  • 5.12.2 COMPLEMENTARY TECHNOLOGIES
    • 5.12.2.1 3D Bioprinting
  • 5.12.3 ADJACENT TECHNOLOGIES
    • 5.12.3.1 Organ-on-a-Chip
• 5.13 KEY CONFERENCES AND EVENTS IN 2024-2025
• 5.14 TRENDS/DISRUPTIONS IMPACTING CUSTOMER'S BUSINESS
• 5.15 INVESTMENT AND FUNDING SCENARIO
• 5.16 CASE STUDY ANALYSIS
  • 5.16.1 CASE STUDY 1: EVALUATION OF PATIENT-DERIVED ORGANOIDS FOR DRUG SENSITIVITY TESTING IN METASTATIC COLORECTAL CANCER WITH LIMITED TREATMENT OPTIONS
  • 5.16.2 CASE STUDY 2: DEVELOPING STABLE ORGANOID MODELS FROM GASTRIC CANCER TISSUES FOR PERSONALIZED MEDICINE AND DRUG SCREENING
  • 5.16.3 CASE STUDY 3: OPTIMAL CULTIVATION PERIODS FOR BLADDER CANCER ORGANOIDS BASED ON TRANSCRIPTOMIC PLASTICITY
• 5.17 IMPACT OF AI ON HUMAN ORGANOIDS MARKET
  • 5.17.1 KEY USE CASES

6 HUMAN ORGANOIDS MARKET, BY PRODUCT

• 6.1 INTRODUCTION
• 6.2 LIVER MODELS
  • 6.2.1 2D LIVER MODELS
    • 6.2.1.1 Fresh hepatocytes
      • 6.2.1.1.1 Increased drug metabolism studies to drive market
    • 6.2.1.2 Cryopreserved hepatocytes
      • 6.2.1.2.1 High quality and response to support market growth
    • 6.2.1.3 Other 2D liver models
  • 6.2.2 3D LIVER MODELS
    • 6.2.2.1 Liver organoids
      • 6.2.2.1.1 Support for determining pharmacology and hepatic toxicity of drugs to treat NAFLD
    • 6.2.2.2 3D bioprinted liver models
      • 6.2.2.2.1 Increased use in drug discovery to propel market growth
    • 6.2.2.3 Liver spheroids
      • 6.2.2.3.1 Need for better approaches in drug discovery to promote adoption of spheroids
    • 6.2.2.4 Liver-on-a-chip
      • 6.2.2.4.1 Stricter regulations on animal testing to promote adoption of in vitro systems like liver-on-a-chip
    • 6.2.2.5 Other 3D liver models
• 6.3 KIDNEY MODELS
  • 6.3.1 2D KIDNEY MODELS
    • 6.3.1.1 Fresh kidney cells
      • 6.3.1.1.1 Accurate representation and functionality to support usage
    • 6.3.1.2 Cryopreserved kidney cells
      • 6.3.1.2.1 Long-term storage benefits to drive market
    • 6.3.1.3 Other 2D kidney models
  • 6.3.2 3D KIDNEY MODELS
    • 6.3.2.1 Kidney organoids
      • 6.3.2.1.1 Increasing incidence of chronic kidney disease to boost market growth
    • 6.3.2.2 3D bioprinted kidney models
      • 6.3.2.2.1 High cost of bioprinting to hinder market growth
    • 6.3.2.3 Kidney spheroids
      • 6.3.2.3.1 Feasibility of studying challenging kidney diseases to drive adoption
    • 6.3.2.4 Other 3D kidney models
• 6.4 PANCREATIC MODELS
  • 6.4.1 2D PANCREATIC MODELS
    • 6.4.1.1 Fresh pancreatic cells
      • 6.4.1.1.1 High responsiveness to stimuli to support demand
    • 6.4.1.2 Cryopreserved pancreatic cells
      • 6.4.1.2.1 Potential use of cryopreserved cells in regenerative therapies and transplantation to increase demand
    • 6.4.1.3 Other 2D pancreatic models
  • 6.4.2 3D PANCREATIC MODELS
    • 6.4.2.1 Pancreatic organoids
      • 6.4.2.1.1 Increasing prevalence of diabetes and pancreatic cancer to drive uptake of pancreatic organoids
    • 6.4.2.2 3D bioprinted pancreatic models
      • 6.4.2.2.1 Precise fabrication and close resemblance to native architecture to drive adoption
    • 6.4.2.3 Pancreatic spheroids
      • 6.4.2.3.1 Improved methods for 3D cell culture to promote spheroid formation and support market growth
    • 6.4.2.4 Other 3D pancreatic models
• 6.5 COLORECTAL MODELS
  • 6.5.1 2D COLORECTAL MODELS
    • 6.5.1.1 Fresh colorectal cells
      • 6.5.1.1.1 Increasing incidence of colorectal cancer worldwide to heighten demand for fresh cells
    • 6.5.1.2 Cryopreserved colorectal cells
      • 6.5.1.2.1 Ability to thaw and culture cells on demand to support efficient research process, reducing need for continuous tissue sourcing
    • 6.5.1.3 Other 2D colorectal models
  • 6.5.2 3D COLORECTAL MODELS
    • 6.5.2.1 Colorectal organoids
      • 6.5.2.1.1 Drive to enhance therapeutic interventions will support growth
    • 6.5.2.2 3D bioprinted colorectal models
      • 6.5.2.2.1 Increasing bioburden of colorectal cancer to drive market growth
    • 6.5.2.3 Colorectal spheroids
      • 6.5.2.3.1 Advantages in determining disease mechanisms and drug testing to drive adoption
    • 6.5.2.4 Other 3D colorectal models
• 6.6 HEART MODELS
  • 6.6.1 2D HEART MODELS
    • 6.6.1.1 Fresh heart cells
      • 6.6.1.1.1 Importance in regenerative medicine applications to support adoption
    • 6.6.1.2 Cryopreserved heart cells
      • 6.6.1.2.1 On-demand access for clinical or research use to drive uptake of cryopreserved cells
    • 6.6.1.3 Other 2D heart models
  • 6.6.2 3D HEART MODELS
    • 6.6.2.1 Heart organoids
      • 6.6.2.1.1 Rising demand in cardiogenesis research to propel market growth
    • 6.6.2.2 3D bioprinted heart models
      • 6.6.2.2.1 High production costs to hinder adoption
    • 6.6.2.3 Heart spheroids
      • 6.6.2.3.1 Challenges in controlling spheroid morphology to restrain growth
    • 6.6.2.4 Other 3D heart models
• 6.7 LUNG MODELS
  • 6.7.1 2D LUNG MODELS
    • 6.7.1.1 Fresh lung cells
      • 6.7.1.1.1 Use of fresh lung cells gaining momentum due to their ability to accurately replicate native lung environment
    • 6.7.1.2 Cryopreserved lung cells
      • 6.7.1.2.1 Advancements in slicing and cryopreservation to enable creation of thousands of hPCLS from a single lung
    • 6.7.1.3 Other 2D lung models
  • 6.7.2 3D LUNG MODELS
    • 6.7.2.1 Lung organoids
      • 6.7.2.1.1 Increased adoption in biological research areas to boost market growth
    • 6.7.2.2 3D bioprinted lung models
      • 6.7.2.2.1 Advancements in bioinks to support uptake of 3D bioprinted lung models
    • 6.7.2.3 Lung spheroids
      • 6.7.2.3.1 Advantages of physiologically relevant environments for evaluating drug efficacy and toxicity to support usage
    • 6.7.2.4 Other 3D lung models
• 6.8 OTHER PRODUCTS
  • 6.8.1 2D MODELS (OTHER PRODUCTS)
    • 6.8.1.1 Fresh cells (other products)
      • 6.8.1.1.1 New techniques for isolating and preserving fresh cells to help enhance quality of research
    • 6.8.1.2 Cryopreserved cells (other products)
      • 6.8.1.2.1 Long-term storage benefits and advancements in research to support adoption
    • 6.8.1.3 Other 2D models
  • 6.8.2 3D MODELS (OTHER PRODUCTS)
    • 6.8.2.1 Organoids (other products)
      • 6.8.2.1.1 Growing focus on collaboration fosters innovation in organoid development
    • 6.8.2.2 3D bioprinted models (other products)
      • 6.8.2.2.1 Lack of suitable bioinks for 3D bioprinting applications to hamper market growth
    • 6.8.2.3 Spheroids (other products)
      • 6.8.2.3.1 Predictive environment for assessing efficacy and safety to support adoption
    • 6.8.2.4 Other 3D models (other products)

7 HUMAN ORGANOIDS MARKET, BY SOURCE

• 7.1 INTRODUCTION
• 7.2 ADULT STEM CELLS
  • 7.2.1 ADULT STEM CELLS TO HOLD LARGEST SHARE OF MARKET, BY SOURCE
• 7.3 INDUCED PLURIPOTENT STEM CELLS
  • 7.3.1 GROWING DEMAND FOR PERSONALIZED MEDICINE TO DRIVE UPTAKE OF IPSCS
• 7.4 EMBRYONIC STEM CELLS
  • 7.4.1 ETHICAL CONCERNS ASSOCIATED WITH ESCS TO HINDER MARKET GROWTH
• 7.5 OTHER SOURCES

8 HUMAN ORGANOIDS MARKET, BY TYPE

• 8.1 INTRODUCTION
• 8.2 READY-TO-USE PRODUCTS
  • 8.2.1 MASS PRODUCTION OF READY-TO-USE PRODUCTS TO DRIVE ADOPTION
• 8.3 CUSTOMIZABLE PRODUCTS
  • 8.3.1 ADVANCEMENTS IN 3D BIOPRINTING TO PROPEL MARKET GROWTH

9 HUMAN ORGANOIDS MARKET, BY CULTURE METHOD

• 9.1 INTRODUCTION
• 9.2 MATRIGEL MATRIX CULTURE
  • 9.2.1 LONG-STANDING USE AND EFFECTIVENESS IN GROWING ORGANOIDS TO ENSURE ADOPTION
• 9.3 AIR-LIQUID INTERFACE CULTURE
  • 9.3.1 INCREASING PREVALENCE OF DISEASES AFFECTING EPITHELIAL TISSUES TO DRIVE ADOPTION
• 9.4 SUSPENSION CULTURE
  • 9.4.1 COST-EFFECTIVENESS OF SUSPENSION CULTURE TO DRIVE MARKET
• 9.5 3D BIOPRINTING CULTURE
  • 9.5.1 RISING DEMAND FOR PERSONALIZED MEDICINE TO BOOST MARKET GROWTH
• 9.6 OTHER CULTURE METHODS

10 HUMAN ORGANOIDS MARKET, BY DISEASE AREA

• 10.1 INTRODUCTION
• 10.2 ONCOLOGY
  • 10.2.1 GROWING FOCUS ON PERSONALIZED MEDICINE IN ONCOLOGY TO DRIVE DEMAND FOR CANCER ORGANOIDS
• 10.3 LIVER DISEASES
  • 10.3.1 INCREASING INCIDENCE OF LIVER-RELATED CONDITIONS TO DRIVE DEMAND FOR EFFECTIVE RESEARCH MODELS
• 10.4 GASTROINTESTINAL DISEASES
  • 10.4.1 WIDE USAGE IN MODELING INFLAMMATORY BOWEL DISEASE AND MALIGNANCIES TO PROPEL MARKET
• 10.5 CARDIOVASCULAR DISEASES
  • 10.5.1 RISING INCIDENCE OF CARDIOVASCULAR DISEASES TO DRIVE MARKET
• 10.6 INFECTIOUS DISEASES
  • 10.6.1 USE OF ORGANOIDS IN DEVELOPING ANTIVIRAL DRUGS TO SUPPORT MARKET GROWTH
• 10.7 NEUROLOGICAL DISORDERS
  • 10.7.1 GROWING INCIDENCE OF NEUROPSYCHIATRIC DISORDERS TO FUEL UPTAKE OF HUMAN ORGANOIDS
• 10.8 OTHER DISEASE AREAS

11 HUMAN ORGANOIDS MARKET, BY APPLICATION

• 11.1 INTRODUCTION
• 11.2 DEVELOPMENTAL BIOLOGY
  • 11.2.1 TECHNOLOGICAL ADVANCEMENTS IN STEM CELL RESEARCH TO BOOST MARKET GROWTH
• 11.3 DRUG TOXICITY & EFFICACY TESTING
  • 11.3.1 INCREASED DRUG DEVELOPMENT COSTS TO DRIVE GROWTH
• 11.4 DISEASE PATHOLOGY
  • 11.4.1 INCREASED DEMAND FOR ADVANCED IN VITRO DISEASE STUDIES TO AUGMENT MARKET GROWTH
• 11.5 PERSONALIZED MEDICINE
  • 11.5.1 HIGH COST AND INSUFFICIENT DATA TO HAMPER MARKET GROWTH
• 11.6 REGENERATIVE MEDICINE
  • 11.6.1 INCREASING FUNDING ACTIVITIES TO PROPEL MARKET GROWTH
• 11.7 OTHER APPLICATIONS

12 HUMAN ORGANOIDS MARKET, BY END USER

• 12.1 INTRODUCTION
• 12.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
  • 12.2.1 INCREASING PREVALENCE OF CHRONIC DISEASES TO PROPEL MARKET GROWTH
• 12.3 CONTRACT RESEARCH ORGANIZATIONS
  • 12.3.1 INCREASING OUTSOURCING OF CLINICAL RESEARCH SERVICES TO SUPPORT MARKET GROWTH
• 12.4 ACADEMIC & RESEARCH INSTITUTES
  • 12.4.1 RISING GOVERNMENT FUNDING AND INCREASING INDUSTRY-ACADEMIA COLLABORATIONS TO DRIVE MARKET
• 12.5 OTHER END USERS

13 HUMAN ORGANOIDS MARKET, BY REGION

• 13.1 INTRODUCTION
• 13.2 NORTH AMERICA
  • 13.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
  • 13.2.2 US
    • 13.2.2.1 Rising prevalence of chronic respiratory diseases and organ transplants to expedite growth
  • 13.2.3 CANADA
    • 13.2.3.1 Growing incidence of cancer and investments in disease diagnostics & life science research to drive market
• 13.3 EUROPE
  • 13.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
  • 13.3.2 GERMANY
    • 13.3.2.1 Higher healthcare spending and organ transplants to favor market growth
  • 13.3.3 UK
    • 13.3.3.1 Rising disease prevalence to drive market growth
  • 13.3.4 FRANCE
    • 13.3.4.1 Increasing availability of advanced medical technologies to support market growth
  • 13.3.5 ITALY
    • 13.3.5.1 Modernization of healthcare infrastructure to support market
  • 13.3.6 SPAIN
    • 13.3.6.1 Rising incidences of cancer to drive demand
  • 13.3.7 REST OF EUROPE
• 13.4 ASIA PACIFIC
  • 13.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
  • 13.4.2 CHINA
    • 13.4.2.1 Healthcare infrastructure improvements to support market growth in China
  • 13.4.3 JAPAN
    • 13.4.3.1 Rising biomedical & medical research to support market growth
  • 13.4.4 INDIA
    • 13.4.4.1 Large patient population and developing healthcare sector to drive market
  • 13.4.5 AUSTRALIA
    • 13.4.5.1 Rising private and public funding for research activities to drive market
  • 13.4.6 SOUTH KOREA
    • 13.4.6.1 Favorable government policies to fuel market growth
  • 13.4.7 REST OF ASIA PACIFIC
• 13.5 LATIN AMERICA
  • 13.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
  • 13.5.2 BRAZIL
    • 13.5.2.1 Growing pharmaceuticals market and budget allocations to boost market
  • 13.5.3 MEXICO
    • 13.5.3.1 Booming medical tourism to support growth
  • 13.5.4 REST OF LATIN AMERICA
• 13.6 MIDDLE EAST & AFRICA
  • 13.6.1 GROWING FOCUS ON IMPROVING QUALITY OF LIFE TO DRIVE MARKET
  • 13.6.2 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA
• 13.7 GCC COUNTRIES
  • 13.7.1 RISING FOCUS ON ADVANCED HEALTH INFRASTRUCTURE TO AUGMENT MARKET
  • 13.7.2 MACROECONOMIC OUTLOOK FOR GCC COUNTRIES

14 COMPETITIVE LANDSCAPE

• 14.1 INTRODUCTION
• 14.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
  • 14.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN HUMAN ORGANOIDS MARKET
• 14.3 REVENUE ANALYSIS, 2021-2023
• 14.4 MARKET SHARE ANALYSIS, 2023
• 14.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
  • 14.5.1 STARS
  • 14.5.2 EMERGING LEADERS
  • 14.5.3 PERVASIVE PLAYERS
  • 14.5.4 PARTICIPANTS
  • 14.5.5 COMPANY FOOTPRINT, KEY PLAYERS, 2023
    • 14.5.5.1 Company footprint
    • 14.5.5.2 Region footprint
    • 14.5.5.3 Product footprint
    • 14.5.5.4 Source footprint
    • 14.5.5.5 Application footprint
• 14.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
  • 14.6.1 PROGRESSIVE COMPANIES
  • 14.6.2 RESPONSIVE COMPANIES
  • 14.6.3 DYNAMIC COMPANIES
  • 14.6.4 STARTING BLOCKS
  • 14.6.5 COMPETITIVE BENCHMARKING OF STARTUP/SME PLAYERS, 2023
• 14.7 COMPANY VALUATION AND FINANCIAL METRICS
• 14.8 BRAND/PRODUCT COMPARATIVE ANALYSIS
  • 14.8.1 BIOIVT
  • 14.8.2 BECYTES BIOTECHNOLOGIES
• 14.9 COMPETITIVE SCENARIO
  • 14.9.1 PRODUCT LAUNCHES
  • 14.9.2 DEALS

15 COMPANY PROFILES

• 15.1 KEY PLAYERS
  • 15.1.1 THERMO FISHER SCIENTIFIC INC.
    • 15.1.1.1 Business overview
    • 15.1.1.2 Products offered
    • 15.1.1.3 Recent developments
      • 15.1.1.3.1 Product launches
      • 15.1.1.3.2 Deals
    • 15.1.1.4 MnM view
      • 15.1.1.4.1 Right to win
      • 15.1.1.4.2 Strategic choices
      • 15.1.1.4.3 Weaknesses and competitive threats
  • 15.1.2 CORNING INCORPORATED
    • 15.1.2.1 Business overview
    • 15.1.2.2 Products offered
    • 15.1.2.3 Recent developments
      • 15.1.2.3.1 Deals
    • 15.1.2.4 MnM view
      • 15.1.2.4.1 Right to win
      • 15.1.2.4.2 Strategic choices
      • 15.1.2.4.3 Weaknesses and competitive threats
  • 15.1.3 MERCK KGAA
    • 15.1.3.1 Business overview
    • 15.1.3.2 Products offered
    • 15.1.3.3 Recent developments
      • 15.1.3.3.1 Deals
      • 15.1.3.3.2 Expansions
    • 15.1.3.4 MnM view
      • 15.1.3.4.1 Right to win
      • 15.1.3.4.2 Strategic choices
      • 15.1.3.4.3 Weaknesses and competitive threats
  • 15.1.4 BIOIVT
    • 15.1.4.1 Business overview
    • 15.1.4.2 Products offered
    • 15.1.4.3 Recent developments
      • 15.1.4.3.1 Deals
    • 15.1.4.4 MnM view
      • 15.1.4.4.1 Right to win
      • 15.1.4.4.2 Strategic choices
      • 15.1.4.4.3 Weaknesses and competitive threats
  • 15.1.5 HUB ORGANOIDS BV
    • 15.1.5.1 Business overview
    • 15.1.5.2 Products offered
    • 15.1.5.3 Recent developments
      • 15.1.5.3.1 Deals
    • 15.1.5.4 MnM view
      • 15.1.5.4.1 Right to win
      • 15.1.5.4.2 Strategic choices
      • 15.1.5.4.3 Weaknesses and competitive threats
  • 15.1.6 BICO
    • 15.1.6.1 Business overview
    • 15.1.6.2 Products offered
    • 15.1.6.3 Recent developments
      • 15.1.6.3.1 Product launches
      • 15.1.6.3.2 Deals
      • 15.1.6.3.3 Other developments
  • 15.1.7 BECYTES BIOTECHNOLOGIES
    • 15.1.7.1 Business overview
    • 15.1.7.2 Products offered
  • 15.1.8 INSPHERO
    • 15.1.8.1 Business overview
    • 15.1.8.2 Products offered
    • 15.1.8.3 Recent developments
      • 15.1.8.3.1 Deals
  • 15.1.9 GBA GROUP
    • 15.1.9.1 Business overview
    • 15.1.9.2 Products offered
    • 15.1.9.3 Recent developments
      • 15.1.9.3.1 Deals
  • 15.1.10 KIRKSTALL LTD.
    • 15.1.10.1 Business overview
    • 15.1.10.2 Products offered
  • 15.1.11 MIMETAS BV
    • 15.1.11.1 Business overview
    • 15.1.11.2 Products offered
    • 15.1.11.3 Recent developments
      • 15.1.11.3.1 Product launches
      • 15.1.11.3.2 Deals
  • 15.1.12 NEUROMICS
    • 15.1.12.1 Business overview
    • 15.1.12.2 Products offered
  • 15.1.13 PRIMACYT CELL CULTURE TECHNOLOGY GMBH
    • 15.1.13.1 Business overview
    • 15.1.13.2 Products offered
  • 15.1.14 STEMCELL TECHNOLOGIES
    • 15.1.14.1 Business overview
    • 15.1.14.2 Products offered
    • 15.1.14.3 Recent developments
      • 15.1.14.3.1 Expansions
• 15.2 OTHER PLAYERS
  • 15.2.1 ACROBIOSYSTEMS
  • 15.2.2 BIOPREDIC INTERNATIONAL
  • 15.2.3 CN BIO INNOVATIONS LTD.
  • 15.2.4 CYPRIO
  • 15.2.5 EMULATE, INC.
  • 15.2.6 KERAFAST, INC.
  • 15.2.7 PANDORUM TECHNOLOGIES PVT. LTD.
  • 15.2.8 CYFUSE BIOMEDICAL KK
  • 15.2.9 NEYROBLASTGX LLC
  • 15.2.10 3DNAMICS INC.
  • 15.2.11 DEFINIGEN LIMITED

16 APPENDIX

• 16.1 DISCUSSION GUIDE
• 16.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
• 16.3 CUSTOMIZATION OPTIONS
• 16.4 RELATED REPORTS
• 16.5 AUTHOR DETAILS

List of Tables

• TABLE 1 INVESTMENTS AND FUNDS FOR HUMAN ORGANOID RESEARCH
• TABLE 2 RESEARCH PROJECTS AND ACTIVITIES
• TABLE 3 AVERAGE SELLING PRICE OF HUMAN ORGANOID PRODUCTS, BY TYPE, 2022-2024
• TABLE 4 AVERAGE SELLING PRICE OF HUMAN ORGANOID PRODUCTS, BY REGION, 2022-2024
• TABLE 5 HUMAN ORGANOIDS MARKET: LIST OF MAJOR PATENTS, 2022-2023
• TABLE 6 IMPORT DATA FOR HS CODE 3002, WHICH INCLUDES CELL CULTURES, WHETHER OR NOT MODIFIED, 2019-2023 (USD MILLION)
• TABLE 7 EXPORT DATA FOR HS CODE 3002, WHICH INCLUDES CELL CULTURES, WHETHER OR NOT MODIFIED, BY COUNTRY, 2019-2023 (USD MILLION)
• TABLE 8 HUMAN ORGANOIDS MARKET: ROLE IN ECOSYSTEM
• TABLE 9 HUMAN ORGANOIDS MARKET: PORTER'S FIVE FORCES
• TABLE 10 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF HUMAN ORGANOIDS (%)
• TABLE 11 KEY BUYING CRITERIA FOR HUMAN ORGANOIDS, BY TYPE
• TABLE 12 NORTH AMERICA: KEY REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
• TABLE 13 EUROPE: KEY REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
• TABLE 14 ASIA PACIFIC: KEY REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
• TABLE 15 LATIN AMERICA: KEY REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
• TABLE 16 REST OF THE WORLD: KEY REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
• TABLE 17 HUMAN ORGANOIDS MARKET: DETAILED LIST OF KEY CONFERENCES AND EVENTS, JANUARY 2024-DECEMBER 2025
• TABLE 18 HUMAN ORGANOIDS MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
• TABLE 19 LIVER MODELS: KEY PRODUCTS OFFERED, BY COMPANY
• TABLE 20 LIVER AND INTRAHEPATIC BILE DUCT CANCER INCIDENCE, 2022
• TABLE 21 HUMAN ORGANOIDS MARKET FOR LIVER MODELS, BY REGION, 2022-2029 (USD MILLION)
• TABLE 22 NORTH AMERICA: HUMAN ORGANOIDS MARKET FOR LIVER MODELS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 23 EUROPE: HUMAN ORGANOIDS MARKET FOR LIVER MODELS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 24 ASIA PACIFIC: HUMAN ORGANOIDS MARKET FOR LIVER MODELS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 25 LATIN AMERICA: HUMAN ORGANOIDS MARKET FOR LIVER MODELS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 26 HUMAN ORGANOIDS MARKET FOR LIVER MODELS, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 27 2D LIVER MODELS MARKET, BY REGION, 2022-2029 (USD MILLION)
• TABLE 28 2D LIVER MODELS MARKET, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 29 FRESH HEPATOCYTES: KEY PRODUCTS OFFERED, BY COMPANY
• TABLE 30 FRESH HEPATOCYTES MARKET, BY REGION, 2022-2029 (USD MILLION)
• TABLE 31 CRYOPRESERVED HEPATOCYTES: KEY PRODUCTS OFFERED, BY COMPANY
• TABLE 32 CRYOPRESERVED HEPATOCYTES MARKET, BY REGION, 2022-2029 (USD MILLION)
• TABLE 33 OTHER 2D LIVER MODELS MARKET, BY REGION, 2022-2029 (USD MILLION)
• TABLE 34 3D LIVER MODELS MARKET, BY REGION, 2022-2029 (USD MILLION)
• TABLE 35 3D LIVER MODELS MARKET, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 36 LIVER ORGANOIDS MARKET, BY REGION, 2022-2029 (USD MILLION)
• TABLE 37 3D BIOPRINTED LIVER MODELS MARKET, BY REGION, 2022-2029 (USD MILLION)
• TABLE 38 LIVER SPHEROIDS MARKET, BY REGION, 2022-2029 (USD MILLION)
• TABLE 39 LIVER-ON-A CHIP MARKET, BY REGION, 2022-2029 (USD MILLION)
• TABLE 40 OTHER 3D LIVER MODELS MARKET, BY REGION, 2022-2029 (USD MILLION)
• TABLE 41 KIDNEY MODELS: KEY PRODUCTS OFFERED, BY COMPANY
• TABLE 42 KIDNEY CANCER INCIDENCE, 2022
• TABLE 43 HUMAN ORGANOIDS MARKET FOR KIDNEY MODELS, BY REGION, 2022-2029 (USD MILLION)
• TABLE 44 NORTH AMERICA: HUMAN ORGANOIDS MARKET FOR KIDNEY MODELS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 45 EUROPE: HUMAN ORGANOIDS MARKET FOR KIDNEY MODELS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 46 ASIA PACIFIC: HUMAN ORGANOIDS MARKET FOR KIDNEY MODELS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 47 LATIN AMERICA: HUMAN ORGANOIDS MARKET FOR KIDNEY MODELS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 48 HUMAN ORGANOIDS MARKET FOR KIDNEY MODELS, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 49 2D KIDNEY MODELS MARKET, BY REGION, 2022-2029 (USD MILLION)
• TABLE 50 2D KIDNEY MODELS MARKET, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 51 FRESH KIDNEY CELLS MARKET, BY REGION, 2022-2029 (USD MILLION)
• TABLE 52 CRYOPRESERVED KIDNEY CELLS MARKET, BY REGION, 2022-2029 (USD MILLION)
• TABLE 53 OTHER 2D KIDNEY MODELS MARKET, BY REGION, 2022-2029 (USD MILLION)
• TABLE 54 3D KIDNEY MODELS MARKET, BY REGION, 2022-2029 (USD MILLION)
• TABLE 55 3D KIDNEY MODELS MARKET, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 56 KIDNEY ORGANOIDS MARKET, BY REGION, 2022-2029 (USD MILLION)
• TABLE 57 3D BIOPRINTED KIDNEY MODELS MARKET, BY REGION, 2022-2029 (USD MILLION)
• TABLE 58 KIDNEY SPHEROIDS MARKET, BY REGION, 2022-2029 (USD MILLION)
• TABLE 59 OTHER 3D KIDNEY MODELS MARKET, BY REGION, 2022-2029 (USD MILLION)
• TABLE 60 PANCREATIC MODELS: KEY PRODUCTS OFFERED, BY COMPANY
• TABLE 61 PANCREATIC CANCER INCIDENCE, 2022
• TABLE 62 HUMAN ORGANOIDS MARKET FOR PANCREATIC MODELS, BY REGION, 2022-2029 (USD MILLION)
• TABLE 63 NORTH AMERICA: HUMAN ORGANOIDS MARKET FOR PANCREATIC MODELS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 64 EUROPE: HUMAN ORGANOIDS MARKET FOR PANCREATIC MODELS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 65 ASIA PACIFIC: HUMAN ORGANOIDS MARKET FOR PANCREATIC MODELS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 66 LATIN AMERICA: HUMAN ORGANOIDS MARKET FOR PANCREATIC MODELS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 67 HUMAN ORGANOIDS MARKET FOR PANCREATIC MODELS, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 68 2D PANCREATIC MODELS MARKET, BY REGION, 2022-2029 (USD MILLION)
• TABLE 69 2D PANCREATIC MODELS MARKET, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 70 FRESH PANCREATIC CELLS MARKET, BY REGION, 2022-2029 (USD MILLION)
• TABLE 71 CRYOPRESERVED PANCREATIC CELLS MARKET, BY REGION, 2022-2029 (USD MILLION)
• TABLE 72 OTHER 2D PANCREATIC MODELS MARKET, BY REGION, 2022-2029 (USD MILLION)
• TABLE 73 3D PANCREATIC MODELS MARKET, BY REGION, 2022-2029 (USD MILLION)
• TABLE 74 3D PANCREATIC MODELS MARKET, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 75 PANCREATIC ORGANOIDS MARKET, BY REGION, 2022-2029 (USD MILLION)
• TABLE 76 3D BIOPRINTED PANCREATIC MODELS MARKET, BY REGION, 2022-2029 (USD MILLION)
• TABLE 77 PANCREATIC SPHEROIDS MARKET, BY REGION, 2022-2029 (USD MILLION)
• TABLE 78 OTHER 3D PANCREATIC MODELS MARKET, BY REGION, 2022-2029 (USD MILLION)
• TABLE 79 COLORECTAL MODELS: KEY PRODUCTS OFFERED, BY COMPANY
• TABLE 80 COLORECTAL CANCER INCIDENCE, 2022
• TABLE 81 HUMAN ORGANOIDS MARKET FOR COLORECTAL MODELS, BY REGION, 2022-2029 (USD MILLION)
• TABLE 82 NORTH AMERICA: HUMAN ORGANOIDS MARKET FOR COLORECTAL MODELS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 83 EUROPE: HUMAN ORGANOIDS MARKET FOR COLORECTAL MODELS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 84 ASIA PACIFIC: HUMAN ORGANOIDS MARKET FOR COLORECTAL MODELS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 85 LATIN AMERICA: HUMAN ORGANOIDS MARKET FOR COLORECTAL MODELS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 86 HUMAN ORGANOIDS MARKET FOR COLORECTAL MODELS, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 87 2D COLORECTAL MODELS MARKET, BY REGION, 2022-2029 (USD MILLION)
• TABLE 88 2D COLORECTAL MODELS MARKET, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 89 FRESH COLORECTAL CELLS MARKET, BY REGION, 2022-2029 (USD MILLION)
• TABLE 90 CRYOPRESERVED COLORECTAL CELLS MARKET, BY REGION, 2022-2029 (USD MILLION)
• TABLE 91 OTHER 2D COLORECTAL MODELS MARKET, BY REGION, 2022-2029 (USD MILLION)
• TABLE 92 3D COLORECTAL MODELS MARKET, BY REGION, 2022-2029 (USD MILLION)
• TABLE 93 3D COLORECTAL MODELS MARKET, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 94 COLORECTAL ORGANOIDS MARKET, BY REGION, 2022-2029 (USD MILLION)
• TABLE 95 3D BIOPRINTED COLORECTAL MODELS MARKET, BY REGION, 2022-2029 (USD MILLION)
• TABLE 96 COLORECTAL SPHEROIDS MARKET, BY REGION, 2022-2029 (USD MILLION)
• TABLE 97 OTHER 3D COLORECTAL MODELS MARKET, BY REGION, 2022-2029 (USD MILLION)
• TABLE 98 HUMAN ORGANOIDS MARKET FOR HEART MODELS, BY REGION, 2022-2029 (USD MILLION)
• TABLE 99 NORTH AMERICA: HUMAN ORGANOIDS MARKET FOR HEART MODELS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 100 EUROPE: HUMAN ORGANOIDS MARKET FOR HEART MODELS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 101 ASIA PACIFIC: HUMAN ORGANOIDS MARKET FOR HEART MODELS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 102 LATIN AMERICA: HUMAN ORGANOIDS MARKET FOR HEART MODELS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 103 HUMAN ORGANOIDS MARKET FOR HEART MODELS, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 104 2D HEART MODELS MARKET, BY REGION, 2022-2029 (USD MILLION)
• TABLE 105 2D HEART MODELS MARKET, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 106 FRESH HEART CELLS MARKET, BY REGION, 2022-2029 (USD MILLION)
• TABLE 107 CRYOPRESERVED HEART CELLS MARKET, BY REGION, 2022-2029 (USD MILLION)
• TABLE 108 OTHER 2D HEART MODELS MARKET, BY REGION, 2022-2029 (USD MILLION)
• TABLE 109 3D HEART MODELS MARKET, BY REGION, 2022-2029 (USD MILLION)
• TABLE 110 3D HEART MODELS MARKET, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 111 HEART ORGANOIDS MARKET, BY REGION, 2022-2029 (USD MILLION)
• TABLE 112 3D BIOPRINTED HEART MODELS MARKET, BY REGION, 2022-2029 (USD MILLION)
• TABLE 113 HEART SPHEROIDS MARKET, BY REGION, 2022-2029 (USD MILLION)
• TABLE 114 OTHER 3D HEART MODELS MARKET, BY REGION, 2022-2029 (USD MILLION)
• TABLE 115 LUNG MODELS: KEY PRODUCTS OFFERED, BY COMPANY
• TABLE 116 LUNG CANCER INCIDENCE,2022
• TABLE 117 HUMAN ORGANOIDS MARKET FOR LUNG MODELS, BY REGION, 2022-2029 (USD MILLION)
• TABLE 118 NORTH AMERICA: HUMAN ORGANOIDS MARKET FOR LUNG MODELS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 119 EUROPE: HUMAN ORGANOIDS MARKET FOR LUNG MODELS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 120 ASIA PACIFIC: HUMAN ORGANOIDS MARKET FOR LUNG MODELS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 121 LATIN AMERICA: HUMAN ORGANOIDS MARKET FOR LUNG MODELS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 122 HUMAN ORGANOIDS MARKET FOR LUNG MODELS, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 123 2D LUNG MODELS MARKET, BY REGION, 2022-2029 (USD MILLION)
• TABLE 124 2D LUNG MODELS MARKET, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 125 FRESH LUNG CELLS MARKET, BY REGION, 2022-2029 (USD MILLION)
• TABLE 126 CRYOPRESERVED LUNG CELLS MARKET, BY REGION, 2022-2029 (USD MILLION)
• TABLE 127 OTHER 2D LUNG MODELS MARKET, BY REGION, 2022-2029 (USD MILLION)
• TABLE 128 3D LUNG MODELS MARKET, BY REGION, 2022-2029 (USD MILLION)
• TABLE 129 3D LUNG MODELS MARKET, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 130 LUNG ORGANOIDS MARKET, BY REGION, 2022-2029 (USD MILLION)
• TABLE 131 3D BIOPRINTED LUNG MODELS MARKET, BY REGION, 2022-2029 (USD MILLION)
• TABLE 132 LUNG SPHEROIDS MARKET, BY REGION, 2022-2029 (USD MILLION)
• TABLE 133 OTHER 3D LUNG MODELS MARKET, BY REGION, 2022-2029 (USD MILLION)
• TABLE 134 OTHER PRODUCTS: KEY PRODUCTS OFFERED, BY COMPANY
• TABLE 135 BRAIN, CENTRAL NERVOUS SYSTEM, AND BREAST CANCER INCIDENCE, 2022
• TABLE 136 OTHER HUMAN ORGANOID PRODUCTS MARKET, BY REGION, 2022-2029 (USD MILLION)
• TABLE 137 NORTH AMERICA: OTHER HUMAN ORGANOID PRODUCTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 138 EUROPE: OTHER HUMAN ORGANOID PRODUCTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 139 ASIA PACIFIC: OTHER HUMAN ORGANOID PRODUCTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 140 LATIN AMERICA: OTHER HUMAN ORGANOID PRODUCTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 141 OTHER HUMAN ORGANOID PRODUCTS MARKET, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 142 2D MODELS (OTHER PRODUCTS) MARKET, BY REGION, 2022-2029 (USD MILLION)
• TABLE 143 2D MODELS (OTHER PRODUCTS) MARKET, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 144 FRESH CELLS (OTHER PRODUCTS) MARKET, BY REGION, 2022-2029 (USD MILLION)
• TABLE 145 CRYOPRESERVED CELLS (OTHER PRODUCTS) MARKET, BY REGION, 2022-2029 (USD MILLION)
• TABLE 146 OTHER 2D MODELS (OTHER PRODUCTS) MARKET, BY REGION, 2022-2029 (USD MILLION)
• TABLE 147 3D MODELS (OTHER PRODUCTS) MARKET, BY REGION, 2022-2029 (USD MILLION)
• TABLE 148 3D MODELS (OTHER PRODUCTS) MARKET, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 149 ORGANOIDS (OTHER PRODUCTS) MARKET, BY REGION, 2022-2029 (USD MILLION)
• TABLE 150 3D BIOPRINTED MODELS (OTHER PRODUCTS) MARKET, BY REGION, 2022-2029 (USD MILLION)
• TABLE 151 SPHEROIDS (OTHER PRODUCTS) MARKET, BY REGION, 2022-2029 (USD MILLION)
• TABLE 152 OTHER 3D MODELS (OTHER PRODUCTS) MARKET, BY REGION, 2022-2029 (USD MILLION)
• TABLE 153 HUMAN ORGANOIDS MARKET, BY SOURCE, 2022-2029 (USD MILLION)
• TABLE 154 ADULT STEM CELLS MARKET, BY REGION, 2022-2029 (USD MILLION)
• TABLE 155 NORTH AMERICA: ADULT STEM CELLS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 156 EUROPE: ADULT STEM CELLS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 157 ASIA PACIFIC: ADULT STEM CELLS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 158 LATIN AMERICA: ADULT STEM CELLS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 159 INDUCED PLURIPOTENT STEM CELLS: KEY PRODUCTS OFFERED, BY COMPANY
• TABLE 160 INDUCED PLURIPOTENT STEM CELLS MARKET, BY REGION, 2022-2029 (USD MILLION)
• TABLE 161 NORTH AMERICA: INDUCED PLURIPOTENT STEM CELLS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 162 EUROPE: INDUCED PLURIPOTENT STEM CELLS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 163 ASIA PACIFIC: INDUCED PLURIPOTENT STEM CELLS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 164 LATIN AMERICA: INDUCED PLURIPOTENT STEM CELLS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 165 EMBRYONIC STEM CELLS MARKET, BY REGION, 2022-2029 (USD MILLION)
• TABLE 166 NORTH AMERICA: EMBRYONIC STEM CELLS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 167 EUROPE: EMBRYONIC STEM CELLS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 168 ASIA PACIFIC: EMBRYONIC STEM CELLS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 169 LATIN AMERICA: EMBRYONIC STEM CELLS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 170 OTHER SOURCES: KEY PRODUCTS OFFERED, BY COMPANY
• TABLE 171 OTHER HUMAN ORGANOID SOURCES MARKET, BY REGION, 2022-2029 (USD MILLION)
• TABLE 172 NORTH AMERICA: OTHER HUMAN ORGANOID SOURCES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 173 EUROPE: OTHER HUMAN ORGANOID SOURCES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 174 ASIA PACIFIC: OTHER HUMAN ORGANOID SOURCES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 175 LATIN AMERICA: OTHER HUMAN ORGANOID SOURCES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 176 HUMAN ORGANOIDS MARKET, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 177 READY-TO-USE PRODUCTS MARKET: KEY PRODUCTS, BY COMPANY
• TABLE 178 READY-TO-USE HUMAN ORGANOID PRODUCTS MARKET, BY REGION, 2022-2029 (USD MILLION)
• TABLE 179 NORTH AMERICA: READY-TO-USE HUMAN ORGANOID PRODUCTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 180 EUROPE: READY-TO-USE HUMAN ORGANOID PRODUCTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 181 ASIA PACIFIC: READY-TO-USE HUMAN ORGANOID PRODUCTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 182 LATIN AMERICA: READY-TO-USE HUMAN ORGANOID PRODUCTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 183 CUSTOMIZABLE HUMAN ORGANOID PRODUCTS MARKET, BY REGION, 2022-2029 (USD MILLION)
• TABLE 184 NORTH AMERICA: CUSTOMIZABLE HUMAN ORGANOID PRODUCTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 185 EUROPE: CUSTOMIZABLE HUMAN ORGANOID PRODUCTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 186 ASIA PACIFIC: CUSTOMIZABLE HUMAN ORGANOID PRODUCTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 187 LATIN AMERICA: CUSTOMIZABLE HUMAN ORGANOID PRODUCTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 188 HUMAN ORGANOIDS MARKET, BY CULTURE METHOD, 2022-2029 (USD MILLION)
• TABLE 189 HUMAN ORGANOIDS MARKET FOR MATRIGEL MATRIX CULTURE, BY REGION, 2022-2029 (USD MILLION)
• TABLE 190 NORTH AMERICA: HUMAN ORGANOIDS MARKET FOR MATRIGEL MATRIX CULTURE, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 191 EUROPE: HUMAN ORGANOIDS MARKET FOR MATRIGEL MATRIX CULTURE, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 192 ASIA PACIFIC: HUMAN ORGANOIDS MARKET FOR MATRIGEL MATRIX CULTURE, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 193 LATIN AMERICA: HUMAN ORGANOIDS MARKET FOR MATRIGEL MATRIX CULTURE, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 194 HUMAN ORGANOIDS MARKET FOR AIR-LIQUID INTERFACE CULTURE, BY REGION, 2022-2029 (USD MILLION)
• TABLE 195 NORTH AMERICA: HUMAN ORGANOIDS MARKET FOR AIR-LIQUID INTERFACE CULTURE, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 196 EUROPE: HUMAN ORGANOIDS MARKET FOR AIR-LIQUID INTERFACE CULTURE, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 197 ASIA PACIFIC: HUMAN ORGANOIDS MARKET FOR AIR-LIQUID INTERFACE CULTURE, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 198 LATIN AMERICA: HUMAN ORGANOIDS MARKET FOR AIR-LIQUID INTERFACE CULTURE, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 199 HUMAN ORGANOIDS MARKET FOR SUSPENSION CULTURE, BY REGION, 2022-2029 (USD MILLION)
• TABLE 200 NORTH AMERICA: HUMAN ORGANOIDS MARKET FOR SUSPENSION CULTURE, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 201 EUROPE: HUMAN ORGANOIDS MARKET FOR SUSPENSION CULTURE, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 202 ASIA PACIFIC: HUMAN ORGANOIDS MARKET FOR SUSPENSION CULTURE, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 203 LATIN AMERICA: HUMAN ORGANOIDS MARKET FOR SUSPENSION CULTURE, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 204 HUMAN ORGANOIDS MARKET FOR 3D BIOPRINTING CULTURE, BY REGION, 2022-2029 (USD MILLION)
• TABLE 205 NORTH AMERICA: HUMAN ORGANOIDS MARKET FOR 3D BIOPRINTING CULTURE, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 206 EUROPE: HUMAN ORGANOIDS MARKET FOR 3D BIOPRINTING CULTURE, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 207 ASIA PACIFIC: HUMAN ORGANOIDS MARKET FOR 3D BIOPRINTING CULTURE, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 208 LATIN AMERICA: HUMAN ORGANOIDS MARKET FOR 3D BIOPRINTING CULTURE, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 209 HUMAN ORGANOIDS MARKET FOR OTHER CULTURE METHODS, BY REGION, 2022-2029 (USD MILLION)
• TABLE 210 NORTH AMERICA: HUMAN ORGANOIDS MARKET FOR OTHER CULTURE METHODS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 211 EUROPE: HUMAN ORGANOIDS MARKET FOR OTHER CULTURE METHODS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 212 ASIA PACIFIC: HUMAN ORGANOIDS MARKET FOR OTHER CULTURE METHODS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 213 LATIN AMERICA: HUMAN ORGANOIDS MARKET FOR OTHER CULTURE METHODS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 214 HUMAN ORGANOIDS MARKET, BY DISEASE AREA, 2022-2029 (USD MILLION)
• TABLE 215 INCIDENCE OF CANCER CASES WORLDWIDE, IN 2022 VS 2045, BY CANCER TYPE
• TABLE 216 HUMAN ORGANOIDS MARKET FOR ONCOLOGY, BY REGION, 2022-2029 (USD MILLION)
• TABLE 217 NORTH AMERICA: HUMAN ORGANOIDS MARKET FOR ONCOLOGY, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 218 EUROPE: HUMAN ORGANOIDS MARKET FOR ONCOLOGY, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 219 ASIA PACIFIC: HUMAN ORGANOIDS MARKET FOR ONCOLOGY, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 220 LATIN AMERICA: HUMAN ORGANOIDS MARKET FOR ONCOLOGY, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 221 HUMAN ORGANOIDS MARKET FOR LIVER DISEASES, BY REGION, 2022-2029 (USD MILLION)
• TABLE 222 NORTH AMERICA: HUMAN ORGANOIDS MARKET FOR LIVER DISEASES, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 223 EUROPE: HUMAN ORGANOIDS MARKET FOR LIVER DISEASES, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 224 ASIA PACIFIC: HUMAN ORGANOIDS MARKET FOR LIVER DISEASES, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 225 LATIN AMERICA: HUMAN ORGANOIDS MARKET FOR LIVER DISEASES, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 226 HUMAN ORGANOIDS MARKET FOR GASTROINTESTINAL DISEASES, BY REGION, 2022-2029 (USD MILLION)
• TABLE 227 NORTH AMERICA: HUMAN ORGANOIDS MARKET FOR GASTROINTESTINAL DISEASES, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 228 EUROPE: HUMAN ORGANOIDS MARKET FOR GASTROINTESTINAL DISEASES, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 229 ASIA PACIFIC: HUMAN ORGANOIDS MARKET FOR GASTROINTESTINAL DISEASES, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 230 LATIN AMERICA: HUMAN ORGANOIDS MARKET FOR GASTROINTESTINAL DISEASES, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 231 HUMAN ORGANOIDS MARKET FOR CARDIOVASCULAR DISEASES, BY REGION, 2022-2029 (USD MILLION)
• TABLE 232 NORTH AMERICA: HUMAN ORGANOIDS MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 233 EUROPE: HUMAN ORGANOIDS MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 234 ASIA PACIFIC: HUMAN ORGANOIDS MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 235 LATIN AMERICA: HUMAN ORGANOIDS MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 236 HUMAN ORGANOIDS MARKET FOR INFECTIOUS DISEASES BY REGION, 2022-2029 (USD MILLION)
• TABLE 237 NORTH AMERICA: HUMAN ORGANOIDS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 238 EUROPE: HUMAN ORGANOIDS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 239 ASIA PACIFIC: HUMAN ORGANOIDS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 240 LATIN AMERICA: HUMAN ORGANOIDS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 241 HUMAN ORGANOIDS MARKET FOR NEUROLOGICAL DISORDERS, BY REGION, 2022-2029 (USD MILLION)
• TABLE 242 NORTH AMERICA: HUMAN ORGANOIDS MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 243 EUROPE: HUMAN ORGANOIDS MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 244 ASIA PACIFIC: HUMAN ORGANOIDS MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 245 LATIN AMERICA: HUMAN ORGANOIDS MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 246 HUMAN ORGANOIDS MARKET FOR OTHER DISEASE AREAS, BY REGION, 2022-2029 (USD MILLION)
• TABLE 247 NORTH AMERICA: HUMAN ORGANOIDS MARKET FOR OTHER DISEASE AREAS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 248 EUROPE: HUMAN ORGANOIDS MARKET FOR OTHER DISEASE AREAS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 249 ASIA PACIFIC: HUMAN ORGANOIDS MARKET FOR OTHER DISEASE AREAS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 250 LATIN AMERICA: HUMAN ORGANOIDS MARKET FOR OTHER DISEASE AREAS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 251 HUMAN ORGANOIDS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
• TABLE 252 HUMAN ORGANOIDS MARKET FOR DEVELOPMENTAL BIOLOGY, BY REGION, 2022-2029 (USD MILLION)
• TABLE 253 NORTH AMERICA: HUMAN ORGANOIDS MARKET FOR DEVELOPMENTAL BIOLOGY, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 254 EUROPE: HUMAN ORGANOIDS MARKET FOR DEVELOPMENTAL BIOLOGY, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 255 ASIA PACIFIC: HUMAN ORGANOIDS MARKET FOR DEVELOPMENTAL BIOLOGY, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 256 LATIN AMERICA: HUMAN ORGANOIDS MARKET FOR DEVELOPMENTAL BIOLOGY, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 257 HUMAN ORGANOIDS MARKET FOR DRUG TOXICITY & EFFICACY TESTING, BY REGION, 2022-2029 (USD MILLION)
• TABLE 258 NORTH AMERICA: HUMAN ORGANOIDS MARKET FOR DRUG TOXICITY & EFFICACY TESTING, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 259 EUROPE: HUMAN ORGANOIDS MARKET FOR DRUG TOXICITY & EFFICACY TESTING, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 260 ASIA PACIFIC: HUMAN ORGANOIDS MARKET FOR DRUG TOXICITY & EFFICACY TESTING, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 261 LATIN AMERICA: HUMAN ORGANOIDS MARKET FOR DRUG TOXICITY & EFFICACY TESTING, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 262 HUMAN ORGANOIDS MARKET FOR DISEASE PATHOLOGY, BY REGION, 2022-2029 (USD MILLION)
• TABLE 263 NORTH AMERICA: HUMAN ORGANOIDS MARKET FOR DISEASE PATHOLOGY, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 264 EUROPE: HUMAN ORGANOIDS MARKET FOR DISEASE PATHOLOGY, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 265 ASIA PACIFIC: HUMAN ORGANOIDS MARKET FOR DISEASE PATHOLOGY, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 266 LATIN AMERICA: HUMAN ORGANOIDS MARKET FOR DISEASE PATHOLOGY, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 267 HUMAN ORGANOIDS MARKET FOR PERSONALIZED MEDICINE, BY REGION, 2022-2029 (USD MILLION)
• TABLE 268 NORTH AMERICA: HUMAN ORGANOIDS MARKET FOR PERSONALIZED MEDICINE, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 269 EUROPE: HUMAN ORGANOIDS MARKET FOR PERSONALIZED MEDICINE, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 270 ASIA PACIFIC: HUMAN ORGANOIDS MARKET FOR PERSONALIZED MEDICINE, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 271 LATIN AMERICA: HUMAN ORGANOIDS MARKET FOR PERSONALIZED MEDICINE, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 272 HUMAN ORGANOIDS MARKET FOR REGENERATIVE MEDICINE, BY REGION, 2022-2029 (USD MILLION)
• TABLE 273 NORTH AMERICA: HUMAN ORGANOIDS MARKET FOR REGENERATIVE MEDICINE, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 274 EUROPE: HUMAN ORGANOIDS MARKET FOR REGENERATIVE MEDICINE, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 275 ASIA PACIFIC: HUMAN ORGANOIDS MARKET FOR REGENERATIVE MEDICINE, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 276 LATIN AMERICA: HUMAN ORGANOIDS MARKET FOR REGENERATIVE MEDICINE, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 277 HUMAN ORGANOIDS MARKET FOR OTHER APPLICATIONS, BY REGION, 2022-2029 (USD MILLION)
• TABLE 278 NORTH AMERICA: HUMAN ORGANOIDS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 279 EUROPE: HUMAN ORGANOIDS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 280 ASIA PACIFIC: HUMAN ORGANOIDS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 281 LATIN AMERICA: HUMAN ORGANOIDS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 282 HUMAN ORGANOIDS MARKET, BY END USER, 2022-2029 (USD MILLION)
• TABLE 283 HUMAN ORGANOIDS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2022-2029 (USD MILLION)
• TABLE 284 NORTH AMERICA: HUMAN ORGANOIDS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 285 EUROPE: HUMAN ORGANOIDS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 286 ASIA PACIFIC: HUMAN ORGANOIDS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 287 LATIN AMERICA: HUMAN ORGANOIDS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 288 HUMAN ORGANOIDS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2022-2029 (USD MILLION)
• TABLE 289 NORTH AMERICA: HUMAN ORGANOIDS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 290 EUROPE: HUMAN ORGANOIDS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 291 ASIA PACIFIC: HUMAN ORGANOIDS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 292 LATIN AMERICA: HUMAN ORGANOIDS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 293 HUMAN ORGANOIDS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2022-2029 (USD MILLION)
• TABLE 294 NORTH AMERICA: HUMAN ORGANOIDS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 295 EUROPE: HUMAN ORGANOIDS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 296 ASIA PACIFIC: HUMAN ORGANOIDS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 297 LATIN AMERICA: HUMAN ORGANOIDS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 298 HUMAN ORGANOIDS MARKET FOR OTHER END USERS, BY REGION, 2022-2029 (USD MILLION)
• TABLE 299 NORTH AMERICA: HUMAN ORGANOIDS MARKET FOR OTHER END USERS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 300 EUROPE: HUMAN ORGANOIDS MARKET FOR OTHER END USERS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 301 ASIA PACIFIC: HUMAN ORGANOIDS MARKET FOR OTHER END USERS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 302 LATIN AMERICA: HUMAN ORGANOIDS MARKET FOR OTHER END USERS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 303 HUMAN ORGANOIDS MARKET, BY REGION, 2022-2029 (USD MILLION)
• TABLE 304 NORTH AMERICA: ESTIMATED NUMBER OF NEW CANCER CASES FROM 0 TO 85+ YEARS OF AGE, 2022-2045
• TABLE 305 NORTH AMERICA: HUMAN ORGANOIDS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 306 NORTH AMERICA: HUMAN ORGANOIDS MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
• TABLE 307 NORTH AMERICA: HUMAN ORGANOIDS MARKET, BY SOURCE, 2022-2029 (USD MILLION)
• TABLE 308 NORTH AMERICA: HUMAN ORGANOIDS MARKET, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 309 NORTH AMERICA: HUMAN ORGANOIDS MARKET, BY CULTURE METHOD, 2022-2029 (USD MILLION)
• TABLE 310 NORTH AMERICA: HUMAN ORGANOIDS MARKET, BY DISEASE AREA, 2022-2029 (USD MILLION)
• TABLE 311 NORTH AMERICA: HUMAN ORGANOIDS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
• TABLE 312 NORTH AMERICA: HUMAN ORGANOIDS MARKET, BY END USER, 2022-2029 (USD MILLION)
• TABLE 313 US: CANCER INCIDENCE, MORTALITY, AND PREVALENCE, BY TYPE, 2022
• TABLE 314 US: HUMAN ORGANOIDS MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
• TABLE 315 US: HUMAN ORGANOIDS MARKET, BY SOURCE, 2022-2029 (USD MILLION)
• TABLE 316 US: HUMAN ORGANOIDS MARKET, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 317 US: HUMAN ORGANOIDS MARKET, BY CULTURE METHOD, 2022-2029 (USD MILLION)
• TABLE 318 US: HUMAN ORGANOIDS MARKET, BY DISEASE AREA, 2022-2029 (USD MILLION)
• TABLE 319 US: HUMAN ORGANOIDS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
• TABLE 320 US: HUMAN ORGANOIDS MARKET, BY END USER, 2022-2029 (USD MILLION)
• TABLE 321 ESTIMATED PREVALENCE OF DIABETES IN CANADA, 2022 VS. 2023
• TABLE 322 CANADA: FIVE MOST-REPORTED CAUSES OF CANCER-RELATED MORTALITY, 2024
• TABLE 323 CANADA: HUMAN ORGANOIDS MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
• TABLE 324 CANADA: HUMAN ORGANOIDS MARKET, BY SOURCE, 2022-2029 (USD MILLION)
• TABLE 325 CANADA: HUMAN ORGANOIDS MARKET, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 326 CANADA: HUMAN ORGANOIDS MARKET, BY CULTURE METHOD, 2022-2029 (USD MILLION)
• TABLE 327 CANADA: HUMAN ORGANOIDS MARKET, BY DISEASE AREA, 2022-2029 (USD MILLION)
• TABLE 328 CANADA: HUMAN ORGANOIDS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
• TABLE 329 CANADA: HUMAN ORGANOIDS MARKET, BY END USER, 2022-2029 (USD MILLION)
• TABLE 330 EUROPE: ESTIMATED NUMBER OF NEW CANCER CASES FROM 2022 TO 2045, BOTH SEXES, AGE [0-85+]
• TABLE 331 EUROPE: HUMAN ORGANOIDS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 332 EUROPE: HUMAN ORGANOIDS MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
• TABLE 333 EUROPE: HUMAN ORGANOIDS MARKET, BY SOURCE, 2022-2029 (USD MILLION)
• TABLE 334 EUROPE: HUMAN ORGANOIDS MARKET, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 335 EUROPE: HUMAN ORGANOIDS MARKET, BY CULTURE METHOD, 2022-2029 (USD MILLION)
• TABLE 336 EUROPE: HUMAN ORGANOIDS MARKET, BY DISEASE AREA, 2022-2029 (USD MILLION)
• TABLE 337 EUROPE: HUMAN ORGANOIDS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
• TABLE 338 EUROPE: HUMAN ORGANOIDS MARKET, BY END USER, 2022-2029 (USD MILLION)
• TABLE 339 GERMANY: CANCER INCIDENCE, MORTALITY, AND PREVALENCE, BY TYPE, 2022
• TABLE 340 GERMANY: HUMAN ORGANOIDS MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
• TABLE 341 GERMANY: HUMAN ORGANOIDS MARKET, BY SOURCE, 2022-2029 (USD MILLION)
• TABLE 342 GERMANY: HUMAN ORGANOIDS MARKET, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 343 GERMANY: HUMAN ORGANOIDS MARKET, BY CULTURE METHOD, 2022-2029 (USD MILLION)
• TABLE 344 GERMANY: HUMAN ORGANOIDS MARKET, BY DISEASE AREA, 2022-2029 (USD MILLION)
• TABLE 345 GERMANY: HUMAN ORGANOIDS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
• TABLE 346 GERMANY: HUMAN ORGANOIDS MARKET, BY END USER, 2022-2029 (USD MILLION)
• TABLE 347 UK: INCIDENCE AND MORTALITY RATE OF HEART AND CIRCULATORY DISEASES (CVD), 2024
• TABLE 348 UK: CANCER INCIDENCE, MORTALITY, AND PREVALENCE, BY TYPE, 2022
• TABLE 349 UK: HUMAN ORGANOIDS MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
• TABLE 350 UK: HUMAN ORGANOIDS MARKET, BY SOURCE, 2022-2029 (USD MILLION)
• TABLE 351 UK: HUMAN ORGANOIDS MARKET, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 352 UK: HUMAN ORGANOIDS MARKET, BY CULTURE METHOD, 2022-2029 (USD MILLION)
• TABLE 353 UK: HUMAN ORGANOIDS MARKET, BY DISEASE AREA, 2022-2029 (USD MILLION)
• TABLE 354 UK: HUMAN ORGANOIDS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
• TABLE 355 UK: HUMAN ORGANOIDS MARKET, BY END USER, 2022-2029 (USD MILLION)
• TABLE 356 FRANCE: CANCER INCIDENCE, MORTALITY, AND PREVALENCE, BY TYPE, 2022
• TABLE 357 FRANCE: HUMAN ORGANOIDS MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
• TABLE 358 FRANCE: HUMAN ORGANOIDS MARKET, BY SOURCE, 2022-2029 (USD MILLION)
• TABLE 359 FRANCE: HUMAN ORGANOIDS MARKET, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 360 FRANCE: HUMAN ORGANOIDS MARKET, BY CULTURE METHOD, 2022-2029 (USD MILLION)
• TABLE 361 FRANCE: HUMAN ORGANOIDS MARKET, BY DISEASE AREA, 2022-2029 (USD MILLION)
• TABLE 362 FRANCE: HUMAN ORGANOIDS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
• TABLE 363 FRANCE: HUMAN ORGANOIDS MARKET, BY END USER, 2022-2029 (USD MILLION)
• TABLE 364 ITALY: CANCER INCIDENCE, MORTALITY, AND PREVALENCE, BY TYPE, 2022
• TABLE 365 ITALY: HUMAN ORGANOIDS MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
• TABLE 366 ITALY: HUMAN ORGANOIDS MARKET, BY SOURCE, 2022-2029 (USD MILLION)
• TABLE 367 ITALY: HUMAN ORGANOIDS MARKET, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 368 ITALY: HUMAN ORGANOIDS MARKET, BY CULTURE METHOD, 2022-2029 (USD MILLION)
• TABLE 369 ITALY: HUMAN ORGANOIDS MARKET, BY DISEASE AREA, 2022-2029 (USD MILLION)
• TABLE 370 ITALY: HUMAN ORGANOIDS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
• TABLE 371 ITALY: HUMAN ORGANOIDS MARKET, BY END USER, 2022-2029 (USD MILLION)
• TABLE 372 SPAIN: CANCER INCIDENCE, 2022 VS 2023
• TABLE 373 SPAIN: HUMAN ORGANOIDS MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
• TABLE 374 SPAIN: HUMAN ORGANOIDS MARKET, BY SOURCE, 2022-2029 (USD MILLION)
• TABLE 375 SPAIN: HUMAN ORGANOIDS MARKET, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 376 SPAIN: HUMAN ORGANOIDS MARKET, BY CULTURE METHOD, 2022-2029 (USD MILLION)
• TABLE 377 SPAIN: HUMAN ORGANOIDS MARKET, BY DISEASE AREA, 2022-2029 (USD MILLION)
• TABLE 378 SPAIN: HUMAN ORGANOIDS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
• TABLE 379 SPAIN: HUMAN ORGANOIDS MARKET, BY END USER, 2022-2029 (USD MILLION)
• TABLE 380 REST OF EUROPE: HUMAN ORGANOIDS MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
• TABLE 381 REST OF EUROPE: HUMAN ORGANOIDS MARKET, BY SOURCE, 2022-2029 (USD MILLION)
• TABLE 382 REST OF EUROPE: HUMAN ORGANOIDS MARKET, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 383 REST OF EUROPE: HUMAN ORGANOIDS MARKET, BY CULTURE METHOD, 2022-2029 (USD MILLION)
• TABLE 384 REST OF EUROPE: HUMAN ORGANOIDS MARKET, BY DISEASE AREA, 2022-2029 (USD MILLION)
• TABLE 385 REST OF EUROPE: HUMAN ORGANOIDS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
• TABLE 386 REST OF EUROPE: HUMAN ORGANOIDS MARKET, BY END USER, 2022-2029 (USD MILLION)
• TABLE 387 ASIA PACIFIC: ESTIMATED NUMBER OF NEW CANCER CASES FROM 2022 TO 2045, BOTH SEXES, AGE [0-85+]
• TABLE 388 ASIA PACIFIC: HUMAN ORGANOIDS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 389 ASIA PACIFIC: HUMAN ORGANOIDS MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
• TABLE 390 ASIA PACIFIC: HUMAN ORGANOIDS MARKET, BY SOURCE, 2022-2029 (USD MILLION)
• TABLE 391 ASIA PACIFIC: HUMAN ORGANOIDS MARKET, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 392 ASIA PACIFIC: HUMAN ORGANOIDS MARKET, BY CULTURE METHOD, 2022-2029 (USD MILLION)
• TABLE 393 ASIA PACIFIC: HUMAN ORGANOIDS MARKET, BY DISEASE AREA, 2022-2029 (USD MILLION)
• TABLE 394 ASIA PACIFIC: HUMAN ORGANOIDS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
• TABLE 395 ASIA PACIFIC: HUMAN ORGANOIDS MARKET, BY END USER, 2022-2029 (USD MILLION)
• TABLE 396 CHINA: CANCER INCIDENCE, MORTALITY, AND PREVALENCE, BY TYPE, 2022
• TABLE 397 CHINA: HUMAN ORGANOIDS MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
• TABLE 398 CHINA: HUMAN ORGANOIDS MARKET, BY SOURCE, 2022-2029 (USD MILLION)
• TABLE 399 CHINA: HUMAN ORGANOIDS MARKET, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 400 CHINA: HUMAN ORGANOIDS MARKET, BY CULTURE METHOD, 2022-2029 (USD MILLION)
• TABLE 401 CHINA: HUMAN ORGANOIDS MARKET, BY DISEASE AREA, 2022-2029 (USD MILLION)
• TABLE 402 CHINA: HUMAN ORGANOIDS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
• TABLE 403 CHINA: HUMAN ORGANOIDS MARKET, BY END USER, 2022-2029 (USD MILLION)
• TABLE 404 JAPAN: CANCER INCIDENCE, MORTALITY, AND PREVALENCE, BY TYPE, 2022
• TABLE 405 JAPAN: HUMAN ORGANOIDS MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
• TABLE 406 JAPAN: HUMAN ORGANOIDS MARKET, BY SOURCE, 2022-2029 (USD MILLION)
• TABLE 407 JAPAN: HUMAN ORGANOIDS MARKET, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 408 JAPAN: HUMAN ORGANOIDS MARKET, BY CULTURE METHOD, 2022-2029 (USD MILLION)
• TABLE 409 JAPAN: HUMAN ORGANOIDS MARKET, BY DISEASE AREA, 2022-2029 (USD MILLION)
• TABLE 410 JAPAN: HUMAN ORGANOIDS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
• TABLE 411 JAPAN: HUMAN ORGANOIDS MARKET, BY END USER, 2022-2029 (USD MILLION)
• TABLE 412 INDIA: CANCER INCIDENCE, MORTALITY, AND PREVALENCE, BY TYPE, 2022
• TABLE 413 INDIA: HUMAN ORGANOIDS MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
• TABLE 414 INDIA: HUMAN ORGANOIDS MARKET, BY SOURCE, 2022-2029 (USD MILLION)
• TABLE 415 INDIA: HUMAN ORGANOIDS MARKET, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 416 INDIA: HUMAN ORGANOIDS MARKET, BY CULTURE METHOD, 2022-2029 (USD MILLION)
• TABLE 417 INDIA: HUMAN ORGANOIDS MARKET, BY DISEASE AREA, 2022-2029 (USD MILLION)
• TABLE 418 INDIA: HUMAN ORGANOIDS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
• TABLE 419 INDIA: HUMAN ORGANOIDS MARKET, BY END USER, 2022-2029 (USD MILLION)
• TABLE 420 AUSTRALIA: CANCER INCIDENCE, MORTALITY, AND PREVALENCE, BY TYPE, 2022
• TABLE 421 AUSTRALIA: HUMAN ORGANOIDS MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
• TABLE 422 AUSTRALIA: HUMAN ORGANOIDS MARKET, BY SOURCE, 2022-2029 (USD MILLION)
• TABLE 423 AUSTRALIA: HUMAN ORGANOIDS MARKET, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 424 AUSTRALIA: HUMAN ORGANOIDS MARKET, BY CULTURE METHOD, 2022-2029 (USD MILLION)
• TABLE 425 AUSTRALIA: HUMAN ORGANOIDS MARKET, BY DISEASE AREA, 2022-2029 (USD MILLION)
• TABLE 426 AUSTRALIA: HUMAN ORGANOIDS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
• TABLE 427 AUSTRALIA: HUMAN ORGANOIDS MARKET, BY END USER, 2022-2029 (USD MILLION)
• TABLE 428 SOUTH KOREA: CANCER INCIDENCE, MORTALITY AND PREVALENCE, BY TYPE, 2022
• TABLE 429 SOUTH KOREA: HUMAN ORGANOIDS MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
• TABLE 430 SOUTH KOREA: HUMAN ORGANOIDS MARKET, BY SOURCE, 2022-2029 (USD MILLION)
• TABLE 431 SOUTH KOREA: HUMAN ORGANOIDS MARKET, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 432 SOUTH KOREA: HUMAN ORGANOIDS MARKET, BY CULTURE METHOD, 2022-2029 (USD MILLION)
• TABLE 433 SOUTH KOREA: HUMAN ORGANOIDS MARKET, BY DISEASE AREA, 2022-2029 (USD MILLION)
• TABLE 434 SOUTH KOREA: HUMAN ORGANOIDS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
• TABLE 435 SOUTH KOREA: HUMAN ORGANOIDS MARKET, BY END USER, 2022-2029 (USD MILLION)
• TABLE 436 REST OF ASIA PACIFIC: HUMAN ORGANOIDS MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
• TABLE 437 REST OF ASIA PACIFIC: HUMAN ORGANOIDS MARKET, BY SOURCE, 2022-2029 (USD MILLION)
• TABLE 438 REST OF ASIA PACIFIC: HUMAN ORGANOIDS MARKET, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 439 REST OF ASIA PACIFIC: HUMAN ORGANOIDS MARKET, BY CULTURE METHOD, 2022-2029 (USD MILLION)
• TABLE 440 REST OF ASIA PACIFIC: HUMAN ORGANOIDS MARKET, BY DISEASE AREA, 2022-2029 (USD MILLION)
• TABLE 441 REST OF ASIA PACIFIC: HUMAN ORGANOIDS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
• TABLE 442 REST OF ASIA PACIFIC: HUMAN ORGANOIDS MARKET, BY END USER, 2022-2029 (USD MILLION)
• TABLE 443 LATIN AMERICA: ESTIMATED NUMBER OF CANCER NEW CASES FROM 2022 TO 2045, BOTH SEXES, AGE [0-85+]
• TABLE 444 LATIN AMERICA: HUMAN ORGANOIDS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 445 LATIN AMERICA: HUMAN ORGANOIDS MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
• TABLE 446 LATIN AMERICA: HUMAN ORGANOIDS MARKET, BY SOURCE, 2022-2029 (USD MILLION)
• TABLE 447 LATIN AMERICA: HUMAN ORGANOIDS MARKET, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 448 LATIN AMERICA: HUMAN ORGANOIDS MARKET, BY CULTURE METHOD, 2022-2029 (USD MILLION)
• TABLE 449 LATIN AMERICA: HUMAN ORGANOIDS MARKET, BY DISEASE AREA, 2022-2029 (USD MILLION)
• TABLE 450 LATIN AMERICA: HUMAN ORGANOIDS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
• TABLE 451 LATIN AMERICA: HUMAN ORGANOIDS MARKET, BY END USER, 2022-2029 (USD MILLION)
• TABLE 452 BRAZIL: CANCER INCIDENCE, MORTALITY, AND PREVALENCE, BY TYPE, 2022
• TABLE 453 BRAZIL: HUMAN ORGANOIDS MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
• TABLE 454 BRAZIL: HUMAN ORGANOIDS MARKET, BY SOURCE, 2022-2029 (USD MILLION)
• TABLE 455 BRAZIL: HUMAN ORGANOIDS MARKET, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 456 BRAZIL: HUMAN ORGANOIDS MARKET, BY CULTURE METHOD, 2022-2029 (USD MILLION)
• TABLE 457 BRAZIL: HUMAN ORGANOIDS MARKET, BY DISEASE AREA, 2022-2029 (USD MILLION)
• TABLE 458 BRAZIL: HUMAN ORGANOIDS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
• TABLE 459 BRAZIL: HUMAN ORGANOIDS MARKET, BY END USER, 2022-2029 (USD MILLION)
• TABLE 460 MEXICO: CANCER INCIDENCE, MORTALITY, AND PREVALENCE, BY TYPE, 2022
• TABLE 461 MEXICO: HUMAN ORGANOIDS MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
• TABLE 462 MEXICO: HUMAN ORGANOIDS MARKET, BY SOURCE, 2022-2029 (USD MILLION)
• TABLE 463 MEXICO: HUMAN ORGANOIDS MARKET, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 464 MEXICO: HUMAN ORGANOIDS MARKET, BY CULTURE METHOD, 2022-2029 (USD MILLION)
• TABLE 465 MEXICO: HUMAN ORGANOIDS MARKET, BY DISEASE AREA, 2022-2029 (USD MILLION)
• TABLE 466 MEXICO: HUMAN ORGANOIDS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
• TABLE 467 MEXICO: HUMAN ORGANOIDS MARKET, BY END USER, 2022-2029 (USD MILLION)
• TABLE 468 REST OF LATIN AMERICA: HUMAN ORGANOIDS MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
• TABLE 469 REST OF LATIN AMERICA: HUMAN ORGANOIDS MARKET, BY SOURCE, 2022-2029 (USD MILLION)
• TABLE 470 REST OF LATIN AMERICA: HUMAN ORGANOIDS MARKET, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 471 REST OF LATIN AMERICA: HUMAN ORGANOIDS MARKET, BY CULTURE METHOD, 2022-2029 (USD MILLION)
• TABLE 472 REST OF LATIN AMERICA: HUMAN ORGANOIDS MARKET, BY DISEASE AREA, 2022-2029 (USD MILLION)
• TABLE 473 REST OF LATIN AMERICA: HUMAN ORGANOIDS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
• TABLE 474 REST OF LATIN AMERICA: HUMAN ORGANOIDS MARKET, BY END USER, 2022-2029 (USD MILLION)
• TABLE 475 AFRICA: ESTIMATED NUMBER OF NEW CANCER CASES BETWEEN 0 TO 85+ OF AGE, 2022-2045
• TABLE 476 MIDDLE EAST & AFRICA: HUMAN ORGANOIDS MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
• TABLE 477 MIDDLE EAST & AFRICA: HUMAN ORGANOIDS MARKET, BY SOURCE, 2022-2029 (USD MILLION)
• TABLE 478 MIDDLE EAST & AFRICA: HUMAN ORGANOIDS MARKET, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 479 MIDDLE EAST & AFRICA: HUMAN ORGANOIDS MARKET, BY CULTURE METHOD, 2022-2029 (USD MILLION)
• TABLE 480 MIDDLE EAST & AFRICA: HUMAN ORGANOIDS MARKET, BY DISEASE AREA, 2022-2029 (USD MILLION)
• TABLE 481 MIDDLE EAST & AFRICA: HUMAN ORGANOIDS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
• TABLE 482 MIDDLE EAST & AFRICA: HUMAN ORGANOIDS MARKET, BY END USER, 2022-2029 (USD MILLION)
• TABLE 483 GCC COUNTRIES: HUMAN ORGANOIDS MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
• TABLE 484 GCC COUNTRIES: HUMAN ORGANOIDS MARKET, BY SOURCE, 2022-2029 (USD MILLION)
• TABLE 485 GCC COUNTRIES: HUMAN ORGANOIDS MARKET, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 486 GCC COUNTRIES: HUMAN ORGANOIDS MARKET, BY CULTURE METHOD, 2022-2029 (USD MILLION)
• TABLE 487 GCC COUNTRIES: HUMAN ORGANOIDS MARKET, BY DISEASE AREA, 2022-2029 (USD MILLION)
• TABLE 488 GCC COUNTRIES: HUMAN ORGANOIDS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
• TABLE 489 GCC COUNTRIES: HUMAN ORGANOIDS MARKET, BY END USER, 2022-2029 (USD MILLION)
• TABLE 490 OVERVIEW OF STRATEGIES DEPLOYED BY KEY PLAYERS IN HUMAN ORGANOIDS MARKET
• TABLE 491 HUMAN ORGANOIDS MARKET: DEGREE OF COMPETITION
• TABLE 492 HUMAN ORGANOIDS MARKET: REGION FOOTPRINT
• TABLE 493 HUMAN ORGANOIDS MARKET: PRODUCT FOOTPRINT
• TABLE 494 HUMAN ORGANOIDS MARKET: SOURCE FOOTPRINT
• TABLE 495 HUMAN ORGANOIDS MARKET: APPLICATION FOOTPRINT
• TABLE 496 HUMAN ORGANOIDS MARKET: DETAILED LIST OF KEY STARTUP/SME PLAYERS
• TABLE 497 HUMAN ORGANOIDS MARKET: COMPETITIVE BENCHMARKING OF STARTUP/SME PLAYERS
• TABLE 498 HUMAN ORGANOIDS MARKET: PRODUCT LAUNCHES, JANUARY 2021- AUGUST 2024
• TABLE 499 HUMAN ORGANOIDS MARKET: DEALS, JANUARY 2021-AUGUST 2024
• TABLE 500 THERMO FISHER SCIENTIFIC: COMPANY OVERVIEW
• TABLE 501 THERMO FISHER SCIENTIFIC: PRODUCTS OFFERED
• TABLE 502 THERMO FISHER SCIENTIFIC: PRODUCT LAUNCHES, JANUARY 2021-AUGUST 2024
• TABLE 503 THERMO FISHER SCIENTIFIC: DEALS, JANUARY 2021-AUGUST 2024
• TABLE 504 CORNING INCORPORATED: COMPANY OVERVIEW
• TABLE 505 CORNING INCORPORATED: PRODUCTS OFFERED
• TABLE 506 CORNING INCORPORATED: DEALS, JANUARY 2021-AUGUST 2024
• TABLE 507 MERCK: COMPANY OVERVIEW
• TABLE 508 MERCK: PRODUCTS OFFERED
• TABLE 509 MERCK: DEALS, JANUARY 2021-AUGUST 2024
• TABLE 510 MERCK: EXPANSIONS, JANUARY 2021-AUGUST 2024
• TABLE 511 BIOIVT: COMPANY OVERVIEW
• TABLE 512 BIOIVT: PRODUCTS OFFERED
• TABLE 513 BIOIVT: DEALS, JANUARY 2021-AUGUST 2024
• TABLE 514 HUB ORGANOIDS: COMPANY OVERVIEW
• TABLE 515 HUB ORGANOIDS: PRODUCTS OFFERED
• TABLE 516 HUB ORGANOIDS: DEALS, JANUARY 2021-AUGUST 2024
• TABLE 517 BICO: COMPANY OVERVIEW
• TABLE 518 BICO: PRODUCTS OFFERED
• TABLE 519 BICO: PRODUCT LAUNCHES, JANUARY 2021-AUGUST 2024
• TABLE 520 BICO: DEALS, JANUARY 2021-JUNE 2024
• TABLE 521 BICO: OTHER DEVELOPMENTS, JANUARY 2021-AUGUST 2024
• TABLE 522 BECYTES BIOTECHNOLOGIES: COMPANY OVERVIEW
• TABLE 523 BECYTES BIOTECHNOLOGIES: PRODUCTS OFFERED
• TABLE 524 INSPHERO: COMPANY OVERVIEW
• TABLE 525 INSPHERO: PRODUCTS OFFERED
• TABLE 526 INSPHERO: DEALS, JANUARY 2021-AUGUST 2024
• TABLE 527 GBA GROUP: COMPANY OVERVIEW
• TABLE 528 GBA GROUP: PRODUCTS OFFERED
• TABLE 529 GBA GROUP: DEALS, JANUARY 2021-AUGUST 2024
• TABLE 530 KIRKSTALL: COMPANY OVERVIEW
• TABLE 531 KIRKSTALL: PRODUCTS OFFERED
• TABLE 532 MIMETAS: COMPANY OVERVIEW
• TABLE 533 MIMETAS: PRODUCTS OFFERED
• TABLE 534 MIMETAS: PRODUCT LAUNCHES, JANUARY 2021-AUGUST 2024
• TABLE 535 MIMETAS: DEALS, JANUARY 2021-AUGUST 2024
• TABLE 536 NEUROMICS: COMPANY OVERVIEW
• TABLE 537 NEUROMICS: PRODUCTS OFFERED
• TABLE 538 PRIMACYT CELL CULTURE TECHNOLOGY GMBH: COMPANY OVERVIEW
• TABLE 539 PRIMACYT CELL CULTURE TECHNOLOGY GMBH: PRODUCTS OFFERED
• TABLE 540 STEMCELL TECHNOLOGIES: COMPANY OVERVIEW
• TABLE 541 STEMCELL TECHNOLOGIES: PRODUCTS OFFERED
• TABLE 542 STEMCELL TECHNOLOGIES: DEALS, JANUARY 2021-AUGUST 2024
• TABLE 543 STEMCELL TECHNOLOGIES: EXPANSIONS, JANUARY 2021-AUGUST 2024

List of Figures

• FIGURE 1 HUMAN ORGANOIDS MARKET: RESEARCH DESIGN METHODOLOGY
• FIGURE 2 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY SIDE AND DEMAND SIDE PARTICIPANTS
• FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
• FIGURE 4 BOTTOM-UP APPROACH: COMPANY REVENUE ESTIMATION APPROACH
• FIGURE 5 CAGR PROJECTIONS: SUPPLY SIDE ANALYSIS
• FIGURE 6 HUMAN ORGANOIDS MARKET: TOP-DOWN APPROACH
• FIGURE 7 DATA TRIANGULATION METHODOLOGY
• FIGURE 8 HUMAN ORGANOIDS MARKET, BY PRODUCT, 2024 VS. 2029 (USD MILLION)
• FIGURE 9 HUMAN ORGANOIDS MARKET, BY SOURCE, 2024 VS. 2029 (USD MILLION)
• FIGURE 10 HUMAN ORGANOIDS MARKET, BY TYPE, 2024 VS. 2029 (USD MILLION)
• FIGURE 11 HUMAN ORGANOIDS MARKET, BY CULTURE METHOD, 2024 VS. 2029 (USD MILLION)
• FIGURE 12 HUMAN ORGANOIDS MARKET, BY DISEASE AREA, 2024 VS. 2029 (USD MILLION)
• FIGURE 13 HUMAN ORGANOIDS MARKET, BY APPLICATION, 2024 VS. 2029 (USD MILLION)
• FIGURE 14 HUMAN ORGANOIDS MARKET, BY END USER, 2024 VS. 2029 (USD MILLION)
• FIGURE 15 HUMAN ORGANOIDS MARKET, BY REGION, 2024 VS. 2029 (USD MILLION)
• FIGURE 16 GROWING FOCUS ON DEVELOPING ALTERNATIVES FOR ANIMAL TESTING MODELS TO DRIVE MARKET GROWTH
• FIGURE 17 LIVER MODELS TO DOMINATE MARKET TILL 2029
• FIGURE 18 ADULT STEM CELLS SEGMENT TO HOLD LARGEST SHARE TILL 2029
• FIGURE 19 READY-TO-USE PRODUCTS SEGMENT TO RETAIN MARKET LEADERSHIP
• FIGURE 20 DEVELOPMENTAL BIOLOGY AND DRUG TOXICITY & EFFICACY TESTING TO COMMAND LARGEST SHARES
• FIGURE 21 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES SEGMENT TO DOMINATE MARKET IN 2029
• FIGURE 22 ASIA PACIFIC TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD
• FIGURE 23 HUMAN ORGANOIDS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
• FIGURE 24 NUMBER OF CLINICAL TRIALS, BY COUNTRY, 2022
• FIGURE 25 NUMBER OF ARTICLES RELATED TO HUMAN ORGANOIDS, 2018-2023
• FIGURE 26 US: NUMBER OF ORGAN TRANSPLANTS (2024)
• FIGURE 27 AVERAGE SELLING PRICE OF FRESH CELLS (2024)
• FIGURE 28 PATENT ANALYSIS FOR HUMAN ORGANOIDS (JANUARY 2014-DECEMBER 2023)
• FIGURE 29 VALUE CHAIN ANALYSIS: MAJOR VALUE ADDED DURING MANUFACTURING AND ASSEMBLY PHASES
• FIGURE 30 HUMAN ORGANOIDS MARKET: SUPPLY CHAIN ANALYSIS
• FIGURE 31 HUMAN ORGANOIDS MARKET: ECOSYSTEM ANALYSIS
• FIGURE 32 HUMAN ORGANOIDS MARKET: PORTER'S FIVE FORCES ANALYSIS
• FIGURE 33 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF HUMAN ORGANOIDS
• FIGURE 34 KEY BUYING CRITERIA FOR HUMAN ORGANOIDS
• FIGURE 35 HUMAN ORGANOIDS MARKET: TRENDS AND DISRUPTIONS IMPACTING CUSTOMER'S BUSINESS
• FIGURE 36 HUMAN ORGANOIDS MARKET: DEALS AND FUNDING
• FIGURE 37 MARKET POTENTIAL OF AI TO ENHANCE RESEARCH AND DEVELOPMENT IN HUMAN ORGANOIDS MARKET
• FIGURE 38 NORTH AMERICA: HUMAN ORGANOIDS MARKET SNAPSHOT
• FIGURE 39 ASIA PACIFIC: HUMAN ORGANOIDS MARKET SNAPSHOT
• FIGURE 40 REVENUE ANALYSIS OF KEY PLAYERS IN HUMAN ORGANOIDS MARKET (2021-2023)
• FIGURE 41 MARKET SHARE ANALYSIS OF KEY PLAYERS IN HUMAN ORGANOIDS MARKET (2023)
• FIGURE 42 HUMAN ORGANOIDS MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2023
• FIGURE 43 HUMAN ORGANOIDS MARKET: COMPANY FOOTPRINT
• FIGURE 44 HUMAN ORGANOIDS MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2023
• FIGURE 45 EV/EBITDA OF KEY VENDORS
• FIGURE 46 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS
• FIGURE 47 HUMAN ORGANOIDS MARKET: BRAND COMPARISON FOR HEPATOCYTES
• FIGURE 48 THERMO FISHER SCIENTIFIC: COMPANY SNAPSHOT
• FIGURE 49 CORNING INCORPORATED: COMPANY SNAPSHOT
• FIGURE 50 MERCK: COMPANY SNAPSHOT
• FIGURE 51 BICO: COMPANY SNAPSHOT